Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

FASgen develops new diagnostic test for steatohepititis

FASgen : 04 June, 2007  (New Product)
FASgen's serum FAS (fatty acid synthase) ELISA diagnostic research test, FAS-Detect ELISA has been extended to identify Non-Alcoholic Steatohepatitis (NASH).
The current diagnostic technique for this disease is a liver needle biopsy.

While only for research use presently, FASgen anticipates the opportunity for use of the non-invasive FAS-Detect ELISA NASH test in the future will be substantial.

FAS-Detect ELISA is a proprietary product of FASgen Diagnostics, an affiliated FASgen company.

NASH commonly occurs as the result of fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is now rather common among the obese population, with an estimated 25 million adults harbouring NAFLD, with up to five percent of these patients developing NASH.

A significant number of NASH patients go on to develop potentially fatal cirrhosis.

These discoveries by FASgen are part of the company's extensive work in developing therapeutic products to treat obesity by the selective inhibition of FAS and related targets.

Identifying patients with NASH in the future using the FAS-Detect ELISA serum test could select those patients at risk for serious liver disease and those most likely to benefit from proactive therapy.

FASgen is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis.

The company has the exclusive licence from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo